Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O.
Barthel H, et al. Among authors: rohde b.
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6.
Eur J Nucl Med Mol Imaging. 2011.
PMID: 21547601
Clinical Trial.